LON:CEL Celadon Pharmaceuticals (CEL) Share Price, News & Analysis GBX 13.40 0.00 (0.00%) As of 08/6/2025 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Celadon Pharmaceuticals Stock (LON:CEL) Get CEL alerts:Sign Up Key Stats Today's Range 13.40▼ 13.4050-Day Range 13.40▼ 13.4052-Week Range 2.21▼ 83VolumeN/AAverage Volume226,267 shsMarket Capitalization£8.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder. For further information please visit our website www.celadonpharma.com Read More Receive CEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celadon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CEL Stock News HeadlinesCeladon Pharmaceuticals Passes AGM Resolutions and Plans DelistingJuly 1, 2025 | tipranks.comAIM WINNERS & LOSERS: Celadon jumps; Frasers eyes Revolution BeautyJune 9, 2025 | lse.co.ukA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.August 17 at 1:00 AM | Porter & Company (Ad)Celadon Pharmaceuticals Faces Financial Uncertainty Amid Funding EffortsJune 6, 2025 | tipranks.comCeladon Pharmaceuticals faces potential administrationJune 1, 2025 | investing.comCeladon Pharmaceuticals Faces Financial Uncertainty Amid Funding ChallengesMay 30, 2025 | tipranks.comCeladon Pharmaceuticals Terminates Credit Facility Amid Strategic Financial AdjustmentsApril 8, 2025 | tipranks.comCeladon Pharmaceuticals Faces Financial Uncertainty Amid Funding DelaysMarch 31, 2025 | tipranks.comSee More Headlines CEL Stock Analysis - Frequently Asked Questions How have CEL shares performed this year? Celadon Pharmaceuticals' stock was trading at GBX 13.40 at the beginning of the year. Since then, CEL stock has increased by 0.0% and is now trading at GBX 13.40. How do I buy shares of Celadon Pharmaceuticals? Shares of CEL stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Celadon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celadon Pharmaceuticals investors own include AutoZone (AZO), Bahamas Petroleum (BPC), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM) and Bank of America (BAC). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolLON:CEL CIKN/A Webwww.celadonpharma.co.uk Phone44 20 3150 0252FaxN/AEmployees2,780Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (7.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.97 million Net Margins-9,520.00% Pretax MarginN/A Return on Equity-131.82% Return on Assets-34.40% Debt Debt-to-Equity Ratio149.37 Current Ratio2.62 Quick Ratio6.97 Sales & Book Value Annual Sales£123.38 thousand Price / Sales66.61 Cash FlowGBX 4.39 per share Price / Cash Flow3.05 Book ValueGBX 3.80 per share Price / Book3.53Miscellaneous Outstanding Shares61,329,971Free FloatN/AMarket Cap£8.22 million OptionableNot Optionable Beta-0.26 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (LON:CEL) was last updated on 8/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celadon Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Celadon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CEL Stock Alerts